Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Eggermont

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
Melanoma Research|August 1, 1997
The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costsA M Eggermont
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanomaA M Eggermont
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 17, 2000
Adjuvant therapy of malignant melanoma and the role of sentinel node mappingA M Eggermont
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
The role interferon-alpha in malignant melanoma remains to be definedA M Eggermont
Anticancer Research|December 17, 1998
TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectivesA M Eggermont
The Cancer Journal From Scientific American|February 24, 2000
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group programU Keilholz, A M Eggermont
Oncology|March 8, 2000
The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative GroupU Keilholz, A M Eggermont
Surgical Oncology Clinics of North America|October 20, 2001
Research and quality control in surgical oncologyP Therasse, A M Eggermont
Cellular Immunology|July 1, 1987
Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapyA M Eggermont, P H Sugarbaker
British Journal of Cancer|October 1, 1988
Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour modelA M Eggermont, P H Sugarbaker
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
Melanoma Research|August 1, 1997
The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costsA M Eggermont
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanomaA M Eggermont
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 17, 2000
Adjuvant therapy of malignant melanoma and the role of sentinel node mappingA M Eggermont
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
The role interferon-alpha in malignant melanoma remains to be definedA M Eggermont
Anticancer Research|December 17, 1998
TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectivesA M Eggermont
The Cancer Journal From Scientific American|February 24, 2000
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group programU Keilholz, A M Eggermont
Oncology|March 8, 2000
The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative GroupU Keilholz, A M Eggermont
Surgical Oncology Clinics of North America|October 20, 2001
Research and quality control in surgical oncologyP Therasse, A M Eggermont
Cellular Immunology|July 1, 1987
Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapyA M Eggermont, P H Sugarbaker
British Journal of Cancer|October 1, 1988
Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour modelA M Eggermont, P H Sugarbaker
Pageof 18